ASCO: mFOLFIRINOX Improves Survival in Pancreatic Cancer
MONDAY, June 4, 2018 -- The oxaliplatin, leucovorin, irinotecan, and 5-fluorouracil (mFOLFIRINOX) regimen is associated with longer median disease-free and overall survival in pancreatic ductal adenocarcinoma; and, receiving chemotherapy before...
Source: Drugs.com - Pharma News - Category: Pharmaceuticals Source Type: news
More News: Adenocarcinoma | Cancer | Cancer & Oncology | Chemotherapy | Eloxatin | Pancreas | Pancreatic Cancer | Pharmaceuticals